65,437 trials
Bardet-Biedl Syndrome · POMC Deficiency
Primary: Maximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period — 29.4; 44.8; 59.9 nanograms per milliliter (ng/mL)
COVID-19
Primary: Completion of COVID-19 Test — 72; 60 Participants
Asthma
Primary: Change From Baseline to Week 12 in Sleep Disturbance Score Using the Asthma Sleep Disturbance Questionnaire (ASDQ) — -0.88; -0.81 Score on a scale — p=0.512
Polypharmacy
Primary: Medication Reconciliation — 0.14; 0.17 number of discrepancies per medication
HIV Infections
Primary: Total Number of Youth Tested for HIV — 154; 123; 68 Participants
Cancer, Hepatocellular
Primary: Number of Participants With Adverse Events — 9; 9; 8 Participants
Vestibular Diseases
Primary: Vestibulo-ocular Reflex Gain Ratio — 1.15 unitless gain ratio — p=<0.001
Sepsis Syndrome
Primary: Induction of MDSCs — 0.19; 0.11 fold change compared to baseline
Covid19 · Vaccination
Primary: COVID-19 Vaccination Within 3 Months — 137; 98 Participants — p=0.0066
Functional Constipation · Irritable Bowel Syndrome With Constipation
Primary: Functional Constipation (FC) Participants: Change From Baseline in 12-week SBM (Spontaneous Bowel Movement) Frequency Rate (SBMs/Week) During the Study Intervention…
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining (tCFS) at Day 60 — -2.04; -1.65; -2.15; -1.54 tCFS score on a scale of 0 - 20
Metastatic Urothelial Carcinoma · Bladder Cancer
Primary: Count of Participants With Response Measured by RECIST 1.1 — 16 Participants
Miscarriage
Primary: Anxiety Rating — 4.4; 3.94 score on a scale
Schizophrenia
Primary: Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA. — -0.0007; -0.0008; -0.0006; -0.0008 Kicer — p=0.0072
Hypertension
Primary: Pre & Post Survey & Knowledge Test — 85; 100 percentage of questions answered correct